JERUSALEM, October 24, 2017 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP)
(http://www.oramed.com), a clinical-stage pharmaceutical company
focused on the development of oral drug delivery systems, announced
today that the Company will participate in the upcoming
17th Annual Diabetes Technology Meeting, November 2 to November 4, 2017, at the Bethesda
North Marriott Hotel & Conference Center in Bethesda, Maryland, USA. Dr. Miriam Kidron, Oramed's Chief Scientific
Officer, will present an update on Oramed's oral insulin
program.
(Logo:
http://photos.prnewswire.com/prnh/20161109/437571LOGO )
Presentation Details:
17th Annual Diabetes Technology
Meeting
Date: November 2, 2017
Time: 10:50 a.m. ET
Location: Bethesda North Marriott Hotel & Conference
Center in Bethesda
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs currently delivered via
injection. Established in 2006, Oramed's Protein Oral Delivery
(POD[TM]) technology is based on
over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its
proprietary flagship product, an orally ingestible insulin capsule
(ORMD-0801). The Company completed multiple Phase II clinical
trials under an Investigational New Drug application with the U.S.
Food and Drug Administration. In addition, Oramed is developing an
oral GLP-1 analog capsule (ORMD-0901).
For more information, the content of which is not part of this
press release, please visit http://www.oramed.com
Forward-looking statements: This press release contains
forward-looking statements. For example, we are using
forward-looking statements when we discuss our expected clinical
development programs and clinical trials or revolutionizing the
treatment of diabetes with our products. These forward-looking
statements are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent
protection for our product candidates; competition from other
pharmaceutical or biotechnology companies; and our ability to
obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays
or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the U.S. Securities and
Exchange Commission.
Company Contact
Oramed Pharmaceuticals
Josh Hexter
Office: +972-2-566-0001 ext. 2
US: 1-844-9-ORAMED ext. 2
Email: josh@oramed.com
SOURCE Oramed Pharmaceuticals Inc.